Navigation Links
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Date:7/21/2009

SOUTH SAN FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company's lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration (FDA) to design this study, which is required for new chemical entities.

This study evaluated the cardiac safety of picoplatin by determining its effect on the cardiac QT/QTc interval by using time-matched pharmacokinetics and electrocardiograms (ECGs). A total of 45 patients with advanced solid malignancies received 150 mg/m2 picoplatin. The trial was conducted at seven clinical sites in the United States. Results showed no clinical cardiac-related events. In addition, no evidence of a clinically relevant trend in any ECG parameter was demonstrated.

"With these new picoplatin safety data, we continue to make progress toward our goal of initiating the filing in 2009 of a New Drug Application for picoplatin as a second-line treatment for small cell lung cancer, with approval and commercialization targeted for 2010," said Robert De Jager, M.D., chief medical officer of Poniard. "More than 1,100 cancer patients have received picoplatin in clinical studies to date. Additional safety and anticipated efficacy data from our ongoing Phase 3 SPEAR study will provide a strong database to support the NDA filing."

The Company plans to present data from the Phase 1 cardiac safety trial at a medical conference later this year.

About Picoplatin

Picoplatin is a new generation platinum-based chemotherapy agent that is in clinical dev
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , November 27, 2014 ... New Drug (IND) Application with the U.S. Food and ... Hovione,s strategy of developing improved drug delivery options for ... minocycline gel, a novel formulation using a new patented ... of the most widely prescribed oral antibiotics for acne. ...
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
(Date:11/26/2014)... , Nov. 26, 2014  Aethlon Medical, Inc. ... definitive agreement to raise approximately $3.3 million at a ... made by one institutional healthcare focused investor. Each unit consists ... a common share purchase warrant. Each whole warrant entitles ... price of $0.30 for a period of five years ...
Breaking Medicine Technology:Hovione Files its First Investigational New Drug Application With the FDA 2Thoratec Announces Presentations At Investor Conferences For December 2014 2Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3
... , EDISON, N.J. , May 25 ... full-service provider of peer-to-peer medical forums and integrated ... its "Commitment to Compliance" initiative, responding to the ... and promotion.  Recognizing the level of complexity the ...
... 25 Abbott (NYSE: ABT ) today ... Edge-to-Edge REpair STudy) trial, which provide additional details about the ... the two causes of mitral regurgitation (MR) – functional MR ... the 30-day major adverse event rate in the MitraClip arm ...
Cached Medicine Technology:Informed Medical Communications Takes the Lead in Response to FDA's 'Bad Ad Program' 2Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves 2Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves 3Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves 4Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves 5Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves 6
(Date:11/27/2014)... In order to enable people to adapt ... an easy way to avoid touching a toilet seat and/or ... a prototype of the patent-pending Toilet Tamer, a device that ... and/or lid in a more sanitary manner. It avoids direct ... Overall, it promotes good hygiene and peace of mind. The ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 Tylenol ... who were allegedly injured by the medication are continuing ... federal litigation is looking ahead to a status conference ... to a Scheduling Order issued earlier this year, a ... December 16th at 10:00 a.m. Items likely to be ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
Breaking Medicine News(10 mins):Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
... InterACTIVE Nutrition,International Inc., a subsidiary of Natural ... has made another major,breakthrough in the ... order to Panama. InterACTIVE Nutrition brand high ... the health department in Panama.,This is a ...
... Against West Nile Virus Today; ... Disease Endemic in the United States, LYON, ... Group, announced today that it has,signed an exclusive global collaboration ... West Nile vaccine to help fight against,this serious, life-altering and ...
... diet low in carbohydrates may help stunt the growth of ... Prostate Center researchers. The study, in mice, suggests that a ... stall tumor growth. , This study showed that cutting carbohydrates ... Freedland, M.D., a urologist at Duke University Medical Center and ...
... Nov. 13 Babies born just,a few weeks ... during their first,week of life than full-term babies, ... Pediatrics., "We have known from previous studies ... problems like respiratory distress syndrome (RDS),feeding difficulties, temperature ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today announced that ... the market closes on Monday, November,19, 2007. In conjunction ... with the investment community at 5:00 p.m. Eastern Time ... the quarter and other,business developments. Interested parties may ...
... NEW DELHI, India, Nov. 12 ,Seeking to ... (USIBC) Coalition for Healthy India launched its ... comprised of executives from the,most prominent players ... Abbott, Pfizer, IBM, Avesthagen, Excel Life Sciences,Cognizant, ...
Cached Medicine News:Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:A low-carb diet may stunt prostate tumor growth 2Health News:Higher Risk of Death for Babies Born Just a Few Weeks Early, Study Finds 2Health News:USIBC Launches Healthcare Mission to India 2
Convenient clip-activated switch with removable cobalt blue filter attachment....
Portable video magnifier. This powerful new portable unit offers maximum flexibility and control. Includes a wider range of magnification settings, adjustable brightness, and even a tilted screen to ...
... the ideal video magnification solution for ... simple-to-use camera attached to a small ... on a mini xY reading table ... bag. Minimates versatility allows you to ...
... Flipperport brings flexibility and portability together ... main components: a high resolution color camera ... of lightweight glasses that display the magnified ... optimal portability, ease of use and comfort. ...
Medicine Products: